Reduced Paired box 5 (PAX5) levels have important roles in the pathogenesis of human B-cell acute lymphoblastic leukemia. However, the role of PAX5 in human lymphoma remains unclear. We generated PAX5-silenced cells using mantle cell lymphoma (MCL) as a model system. These PAX5 − MCL cells exhibited unexpected phenotypes, including increased proliferation in vitro, enhanced tumor infiltration in vivo, robust adhesion to the bone marrow stromal cells and increased retention of quiescent stem-like cells. These phenotypes were attributed to alterations in the expression of genes including p53 and Rb, and to phosphoinositide 3-kinase/mammalian target of rapamycin and phosphorylated signal transducer and activator of transcription 3 pathway hyperactivation. On PAX5 silencing, the MCL cells displayed upregulated interleukin (IL)-6 expression and increased responses to paracrine IL-6. Moreover, decreased PAX5 levels in CD19+ MCL cells correlated with their increased infiltration and progression; thus, PAX5 levels can be used as a prognostic marker independent of cyclin D1 in advanced MCL patients. Importantly, high-throughput screening of 3800 chemical compounds revealed that PAX5 − MCL cells are highly drug-resistant compared with PAX5 wild-type MCL cells. Collectively, the results of our study support a paradigm shift regarding the functions of PAX5 in human B-cell cancer and encourage future efforts to design effective therapies against MCL.
INTRODUCTION
The transcription factor Paired box 5 (Pax5) has a central role in restricting the differentiation of lymphoid progenitors toward the B-cell lineage. 1 Similar to other PAX family members, Pax5 contains a conserved 'paired' domain, which functions as a bipartite DNA-binding region consisting of N-and C-terminal subdomains. 2 This bipartite domain interacts with degenerate Pax5 consensus binding sites and multiple sequence variants can increase the affinity of one half-site, whereas decreasing the affinity of the other half-site. 3 By the pro-B cell stage, Pax5 is uniformly expressed until it becomes downregulated during plasma cell differentiation. 4, 5 During this physiological downregulation, many Pax5-repressed genes are re-expressed and B-cell-specific gene expression is altered. 6, 7 Pax5-deficient (Pax5 − / − ) pro-B cells can differentiate into functional macrophages, granulocytes, dendritic cells, osteoclasts or natural killer cells in vivo. 7, 8 In addition, Pax5 − / − pro-B cells differentiate in vitro into functional T cells in the presence of OP9 stromal cells expressing the Notch ligand Delta-like 1. 9 Despite its established role as a determinant of normal B-cell lineage commitment, the role of PAX5 in the development and progression of human B-cell cancer is controversial. For example, PAX5 has been implicated in certain lymphomas as an oncogene via a gain-of-function mutation. 10 In contrast, human B-progenitor acute lymphoblastic leukemia harbors monoallelic mutations that reduce PAX5 protein expression. 11 Ablating the Pax5 gene expression in mice leads to spontaneous B-cell malignancies, 12 a finding that supports a role of PAX5 as a potential tumor suppressor. Hence, the exact role of PAX5 in human lymphoma initiation and progression remains enigmatic.
To directly address this controversial issue, we silenced PAX5 expression in mantle cell lymphoma (MCL) cells using lentivirus. MCL accounts for~6% of all non-Hodgkin's lymphomas and most tumors become highly refractory to standard radiation and chemotherapy, contributing to one of the worst survival rates among non-Hodgkin's lymphoma patients. 13 A major genomic abnormality in MCL, which also distinguishes them from lowgrade B-cell lymphoma cases, is the t(11;14)(q13;q32) translocation, which leads to increased cyclin D1 (CCND1) expression due to the juxtaposition of CCND1 with B-cell IgG heavy-chain transcriptional enhancers. 14 However, transgenic mice overexpressing CCND1 in B cells do not develop spontaneous lymphoma, revealing that CCND1 overexpression alone is not sufficient to induce MCL, and that alternative genetic or epigenetic mechanisms are required. 15, 16 Interestingly, silencing PAX5 in MCL resulted in unexpected phenotypes, including increased cell proliferation in vitro, increased tumor infiltration in vivo, increased cell adhesion to bone marrow stromal cells (BMSCs) and increased retention of quiescent stem-like cells, suggesting that decreased PAX5 levels promote tumor progression. Importantly, the PAX5 levels were associated with the clinical outcomes of MCL and drug resistance.
Collectively, our data define novel functions of PAX5 in human MCL, as PAX5 downregulation conferred increased cell proliferation and led to the overexpression of specific prosurvival pathways that contribute to MCL progression and increased tumor infiltration. Our findings support a paradigm shift regarding the functions of PAX5 in human B-cell lymphoma.
MATERIALS AND METHODS

Cell lines
The human MCL cell lines SP53 and Jeko were obtained from the American Type Culture Collection (Manassas, VA, USA). HS5 BMSCs were a kind gift from Dr B Torok-Storb (Fred Hutchinson Cancer Research Center, Seattle, WA, USA). Cells were maintained under standard conditions (5% CO 2 , 37°C). 
Human MCL samples
Relative expression levels
SP53 G1/S/G2 phase CDK6 SKP2 CCND3 CDK2 CCNE1 TFDP1 E2F4 CCNA2 CDK1 CCNB1 CCNB2
Jeko G1/S/G2 phase 
RESULTS
PAX5 silencing increases MCL cell proliferation and PAX5 overexpression induces MCL cell death
We generated two cell lines in which PAX5 was stably knocked down: PAX5 − Jeko and PAX5 − SP53 MCL cells. Lentiviral PAX5 small hairpin RNA transduction efficiently silenced PAX5 expression in GFP+ SP53 and Jeko cells (Supplementary Figure S1a ), whereas PAX5 ORF lentiviral infection generated PAX5overexpressing cells (Supplementary Figure S1b ). We next compared the proliferation of PAX5 − MCL cells with that of control cells transfected with scrambled RNA. Unexpectedly, cell proliferation was significantly increased in PAX5 − MCL cells ( Figure 1a ). In contrast, PAX5 overexpression (PAX5 ORF ) severely reduced cell proliferation ( Figure 1b ) and increased apoptosis in these cells (Supplementary Figure S1c ). PAX5 − MCL cells also thrived under serum-starved conditions; PAX5 − MCL cells exhibited significantly increased cell survival in 2% or 5% serum (Figure 1b and Supplementary Figure S1d ), indicating that silencing PAX5 promotes MCL cell survival not only under normal cell culture conditions but also under stressed conditions.
Cell cycle regulator expression is altered in PAX5 − MCL cells MCL cells included~50%-60% more cells in S phase and 30%-40% fewer cells in G0/G1 phase than in control cells (Supplementary Figure S1e ). Cyclin-dependent kinase (CDK) deregulation has been linked to increased cellular proliferation and genomic and chromosomal instability, and these alterations can contribute to tumor progression. [17] [18] [19] PAX5 − MCL cells demonstrated increased levels of cyclin genes involved in G1 progression, such as CCNE1 and CCNA2 (Figure 1c ), and of corresponding G1 phase-related CDKs, including CDK2, CDK6 ( Figure 1c ) and CDK4 ( Figure 1d ). The deregulation of the gene and protein expression of the tumor suppressors TP53, RB and CDKN1A (p21) leads to lymphoma development. 20, 21 SP53 cells, which harbor wild-type p53, 22, 23 expressed decreased TP53, CDKN1A and CDKN1B levels on PAX5 silencing (Figures 1d and e ). These alterations collectively resulted in increased MCL cell proliferation. Approximately 110 genes are normally repressed by Pax5 in murine B cells. 6, 24 We selected 13 genes that had previously been reported to be involved in cancer development or hematopoietic stem cell function ( Supplementary Table S1 ). Among these 13 Pax5-repressed genes, 10 genes were significantly upregulated in PAX5 − SP53 cells (Supplementary Figure S2 ) and 7 were significantly upregulated in PAX5 − Jeko cells (Supplementary Figure S2 ). These data suggest that PAX5 may control a gene profile contributing to uncontrolled MCL cell proliferation that is similar between human and mouse cells.
PAX5-silenced MCL cells exhibit increased colony-forming capacity and bone marrow engraftment in vivo
We analyzed the colony-forming abilities of PAX5 − MCL cells using phytohemagglutinin leukocyte conditioned medium, which has been used to evaluate the stem-like properties of myeloma. 25 PAX5 silencing significantly increased the number of MCL colonyforming units compared with the control treatment ( Figure 2a ).
We further analyzed the effect of PAX5 gene silencing on stemlike cell engraftment using PKH26 dye as described previously. 26 GFP+-expressing MCL cell engraftment was not different between PAX5 − MCL and control cells after 48 h in vivo. The PKH26+ cellrecovery rate was significantly higher in PAX5 − xenografts than in control xenografts (Figure 2b and Supplementary Table S2 ). Immunohistochemical analysis of the bones and spleens from xenografted mice confirmed our fluorescence-activated cell sorted findings ( Figure 2c ). We observed a quantitative increase of 18.2% and 35% in the engraftment of PAX5 − SP53 and Jeko cells, respectively, compared with the control cells ( Supplementary  Table S2 ).
PAX5 silencing promotes tumor spread in xenografted mice
We first transplanted PAX5 − MCL cells or control cells into NOD/SCID mice via intravenous injection. After 6-8 weeks, we discovered significantly greater numbers of CD45+ and GFP+ cells from the PAX5 − MCL-xenografted mice than in the control mice (Figure 3a and Supplementary Figure S3a ). The differences in cell (Figure 3a ). Immunohistochemistry analyses of frozen tissue sections also displayed greater numbers of CD45+ cells in the bones from PAX5 − MCLxenografted mice (Supplementary Figure S3b ). We then transplanted MCL cells via subcutaneous injection. The PAX5 − MCL-xenografted mice developed larger tumors than the control mice ( Figure 3b ) and this result was confirmed by fluorodeoxyglucose-positron emission tomography and computed tomography imaging analyses (Figure 3c ). Detailed 18 F-fluorodeoxyglucose uptake analyses showed that PAX5 − MCL tumors spread into various sites such as the bone marrows, thymus and lymph nodes ( Figure 3d ). There were also increased infiltration into gastrointestinal tissues in the PAX5 − MCLxenografted mice (Supplementary Figure S3c) .
To further investigate the interaction between MCL cells and the microenvironment, we evaluated the effects of PAX5 silencing on cell adhesion using HS5 BMSCs. Compared with control cells, PAX5 − MCL cells demonstrated markedly increased cell adhesion to the HS5 cell monolayer (Figure 3e ). PAX5 − MCL cells were more mobile than the control cells (Supplementary Figures S3d and j and Supplementary Videos 1 and 2), as the average distance travelled by PAX5 − MCL cells was far greater than that travelled by the control cells (Supplementary Figure S3f) .
Taken together, our data support unexpected functions of PAX5 in human B-cell lymphoma; PAX5 downregulation leads to increased cell proliferation, stem-like properties, motility and cell adhesion, resulting in increased MCL cell infiltration and engraftment in the xenograft mice.
The upregulation of IL-6 leads to hyperactivated STAT3, AKT and MEK signaling in PAX5 − MCL cells We next examined the pathways expressed in various hematological malignancies such as the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and MAPK/ERK (mitogen-activated protein kinase/extracellular signalrelated kinase) signaling pathways. [27] [28] [29] [30] [31] Immunoblottings showed strong activation of AKT/mTOR pathway signaling factors, including pmTOR, p-p70 and pAKT, and this activation could account for the increased proliferation of PAX5 − MCL cells ( Figure 4a ). Phosphorylated ERK and phosphorylated MAPK have been implicated in cell survival, adhesion to the microenvironment and motility; 32 the levels of these factors were also increased in PAX5 − MCL cells ( Figure 4a ). Interestingly, CCND3, which encodes for cyclin D3, an important cyclin for early B-cell growth, 33 was also increased (Supplementary Figure S4a) .
The hyperactivation of the AKT/mTOR and MAPK/ERK signaling pathways in PAX5 − cells implies a possible deregulation of interleukin (IL)-6, an important upstream signaling protein. 34, 35 The IL-6 levels were significantly increased in PAX5 − MCL conditioned media compared with media from control cells; HS5-conditioned medium served as a positive control ( Figure 4b ). Serum restriction has also been reported to induce IL-6 expression 36 and nutrient restriction resulted in markedly increased IL-6 secretion in SP53 PAX5 − cells compared with control cells (Figure 4b ). Alternatively, in Jeko cells, which do not produce autocrine IL-6, 36 PAX5 silencing did not increase IL-6 production (Supplementary Figure S4b) . However, the levels of IL-6, GP80 (an IL-6 receptor) and GP130 (an IL-6 signal transducer) were significantly increased in both PAX5 − SP53 and Jeko cells compared with the corresponding control cells (Figure 4c ). The mRNA levels of the downstream IL-6 targets BCL-XL, MCL1 and S1PR1 were significantly increased after serum restriction in PAX5 − MCL cells compared with control cells (Supplementary Figure S4c ). We used conditioned media from HS5 human BMSCs enriched for IL-6 (ref. 37) (HS5-CM) as an alternative source of paracrine IL-6. Enzyme-linked immunosorbent assay and immunoblot analyses confirmed IL-6 expression in HS5-CM ( Supplementary Figure S4d) . At the steady state (0 h), PAX5 − MCL cells expressed higher pSTAT3 (phosphorylated signal transducer and activator of transcription 3) levels, which increased on HS5 addition compared with control cells (Figure 4d ). Furthermore, treatment with IL-6-neutralizing antibodies reduced pSTAT3 activation when supplemented with HS5-CM (Figure 4e ). Our data suggest that PAX5 downregulation potentiates cells to exert a greater response to exogenous IL-6, potentially leading to increased cell infiltration into the bone marrows (Figure 3a ).
PAX5 silencing facilitates bortezomib resistance via plasmacytic differentiation Doxorubicin and etoposide are commonly used chemotherapeutic agents that can induce p53-mediated cell damage responses. 38, 39 The TP53 transcript levels were significantly decreased in PAX5 − cells within 24 h of doxorubicin treatment (Supplementary Figure  S4e) . Reverse transcriptase-PCR analyses also showed that after 6 or 12 h of etoposide treatment, PAX5 − cells expressed lower TP53 transcript levels (Supplementary Figure S4f) . As expected, based on the TP53 expression responses after drug treatment, PAX5 − SP53 cells were more resistant to doxorubicin treatment (Supplementary Figure S4g) . We further investigated the roles of PAX5 in MCL using the clinically therapeutic agent bortezomib. Bortezomib inhibits proteasomal activity and is widely used to treat relapsed MCL, albeit with varying clinical efficacy due to the drug-resistant tumor cells. 40 PAX5 − MCL cells showed increased resistance to bortezomib and bortezomib-containing regimens (Supplementary Figure S4h ). PAX5 − MCL cells upregulated transcription factors that determine plasmacytic differentiation, such as interferon regulatory factor 4 and Blimp-1, as determined by quantitative reverse transcriptase-PCR (Supplementary Figure S4i) ( Supplementary Figure 4j) . Interestingly, both quantitative reverse transcriptase-PCR and immunoblotting of PAX5 − Jeko cells showed no significant increase in interferon regulatory factor 4 expression; this result was consistent with previous reports using Jeko.BR (bortezomib resistant) subclones. 41 In addition, the expression of the plasma cell marker CD138 was increased in PAX5 − MCL cells (Supplementary Figure S4k ), suggesting that PAX5 downregulation promotes the resistance of MCL cells to bortezomib by facilitating plasmacytic differentiation.
PAX5 downregulation is an indicator of MCL progression and is associated with aggressive blastoid variant MCL
We conducted comprehensive PAX5 level analyses on 39 different primary MCL samples, consisting of 31 peripheral blood and 8 bone marrow aspirate specimens ( Supplementary Table S3 ). All studies were conducted in a blinded manner, in which only CD19+ cells isolated via positive selection were analyzed. Compared with those from normal control blood or bone marrow samples, the PAX5 levels were significantly reduced in CD19+ cells from MCL patient samples (Figures 5a and b) . Interestingly, the PAX5 levels in MCL CD19+ cells from the bone marrow samples were significantly lower than those from the blood samples (Figure 5c ). To determine the experimental relevance of this result, we transplanted unmanipulated SP53 MCL cells into mice via subcutaneous injection. We observed that the PAX5 levels were significantly lower in disseminated human cells isolated from the spleen and the bone marrow than in the localized parental subcutaneous tumor cells ( Supplementary Figure S5a) . PAX5 − MCL-xenografted mice displayed tumor spread to gastrointestinal sites (Supplementary Figure S3c) . Similarly, we found that the PAX5 levels in CD19+ tumor cells were significantly lower in patients with a record of gastrointestinal involvement than in patients without recorded gastrointestinal involvement (Figure 5d ).
Blastoid variant MCL is a highly aggressive but rare MCL subtype that has a worse prognosis than the more common forms of MCL. [42] [43] [44] Analysis of patient samples revealed that blastoid MCL cases contained significantly reduced PAX5 levels compared with non-blastoid MCL cases (Figure 5e ). We then analyzed the CCND1 levels in these samples and found at least a fourfold increase in the expression compared with that of normal B cells ( Supplementary Table S4 and Supplementary Figure S5b ). However, further correlation analysis revealed that CCND1 expression could not predict the survival of MCL patients between blastoid variant and non-blastoid variant MCL (Supplementary Figure S5c) . Moreover, we found that the overall survival of patients displaying PAX5 low was significantly lower than that of patients displaying PAX5 high (Figure 5f and Supplementary Table S5 ). The PAX5 low patients exhibited a survival rate very similar to that of the verified blastoid MCL cases within our data set (Supplementary Figure  S5d ), suggesting that the PAX5 levels can be used to predict survival among advanced MCL patients. Collectively, our data support PAX5 downregulation as an important signaling event in MCL that contributes to the enhanced progression and infiltration of malignant B cells.
High-throughput screening of compounds reveals the drug-resistant nature of PAX5 − MCL cells To further support our understanding regarding the drug-resistant nature of PAX5-silenced MCL cells, we screened 3864 compounds Figure S6a) . A consistent Z′-score of 40.5 across different screening days indicated that the screen was consistent and reliable. 45 A high signal-tonoise ratio was achieved for all three libraries and a scatterplot for each cell type depicted a clear distinction between the control and test compounds ( Supplementary Figures S6b-d) .
Compounds that displayed a difference in efficacy of at least 5% between control and PAX5 − MCL cells were analyzed. After filtering the compounds displaying at least 40% of the inhibitory effect of doxorubicin (high-throughput screening-positive control), we obtained a positive hit rate of 3.7%-7.0% of the compounds in the high-throughput screening libraries. Across all three libraries, the PAX5 − MCL cells were much more resistant than the control cells (Figure 6a ). Further analysis revealed many unique compounds to which PAX5 − MCL cells were resistant (Figures 6b-d) ; these compounds were selected based on their significance as detailed in the Supplementary Methods. We further analyzed the compounds to which PAX5 − MCL cells were resistant and linked these compounds to known biological pathways. Compounds that targeted the PI3K-AKT-mTOR and MEK/ERK signaling cascades were less effective in killing PAX5 − Jeko cells Figure 5 . Decreased PAX5 levels in MCL cells promote lymphoma dispersal and can be used to predict a worse prognosis in MCL patients. (a) CD19+ B cells were isolated from MCL biopsy or apharesis samples (n = 31), or from normal blood (n = 10), and the PAX5 mRNA levels were determined via quantitative reverse transcriptase-PCR (qRT-PCR). Each replicate was performed in triplicate and the expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). (b) CD19+ cells were purified from the bone marrow of normal individuals (n = 8) or MCL patients (n = 8) and the PAX5 mRNA levels determined via qRT-PCR. Each replicate was performed in triplicate and the expression levels were normalized to GAPDH. (c) PAX5 mRNA was downregulated in the bone marrow samples of MCL patients compared with the corresponding blood samples. (d) CD19+ cells isolated from GI-involved MCL patients (n = 5) contained lower levels of PAX5 mRNA than CD19+ cells from non-GI-involved MCL patients (n = 26). (e) CD19+ cells isolated from blastoid MCL patients (n = 12) contained lower levels of PAX5 mRNA than CD19+ cells from non-blastoid MCL patients (n = 19). A list of samples examined in d and e is presented in Supplementary Table S3 . (f) The overall survival of MCL patients was significantly decreased in the PAX5 low population compared with the PAX5 high population (Po0.05; Mantel-Cox curve analysis) (n = 32). 'PAX5 high ' refers to the upper 50% of the PAX5 levels in the MCL patients and 'PAX5 low ' refers to who exhibit lower 50% of the PAX5 levels in the MCL patients. A list of samples is presented in Supplementary Table S5 . *Po 0.05 (vs PAX5 control ; Student's t-test); **P o0.005 (vs PAX5 control ; Student's t-test). n.s., non-significant difference. Figure S6e ), suggesting that PAX5 − MCL cells use hyperactivated PI3K-AKT-mTOR and MEK/ERK signaling pathways to promote their survival.
DISCUSSION
Despite its essential roles in determining and maintaining B-cell identity in mice, 4 the functions of PAX5 in human B malignancies are unclear. We found quantitative differences in PAX5 expression between normal B cells and B cells from MCL patients, which displayed decreased PAX5 levels (Figures 5a and b) . In MCL patients, PAX5 levels were decreased in lymphoma cells from the bone marrow compared with those from the peripheral blood ( Figure 5c ). In xenografted mice, subcutaneous tumor cells contained higher PAX5 levels than human B cells from the bone marrow (Supplementary Figure S5a) . These data support PAX5 downregulation in B cells as an important event for their conversion to malignant B cells and their dispersal during disease progression. However, PAX5 was not absent from MCL cells, suggesting that reduced PAX5 levels may be sufficient to induce global changes in gene expression that result in tumor transformation and progression. When we analyzed the PAX5 levels in the existing MCL database, 46 we were unable to detect a correlation between the PAX5 levels and patient survival. This discrepancy could be due to differences in the methods used to generate the data: the existing database used lymph node biopsies from patients and these samples contain non-B cells and supporting stromal cells. In contrast, our data were based on purified CD19+ B cells. It remains possible that the B cells that we collected contained normal B cells. However, all MCL samples that we used were stage 4 with extranodal site involvement; thus, the number of normal B cells in each sample was minimal. The downregulation of PAX5 levels in tumor cells on infiltration and dissemination suggests that the levels are controlled by epigenetic mechanisms rather than genetic translocation or deletion, as shown in ALL. 11 When we analyzed MCL cells for known PAX5 translocations, none were detected (data not shown). The quantitative differences in the PAX5 expression levels between the tissues collected from MCL patients prompted us to silence the PAX5 gene in MCL cell lines, which are of peripheral blood origin, to characterize the functions of PAX5 in MCL progression.
PAX5 − MCL cells showed a remarkably increased proliferation in vitro and in vivo, whereas PAX5-overexpressing cells exhibited delayed growth and cell death (Figures 1a and b CDKs and decreased expression of tumor suppressor genes such as Rb (Figure 1g ). It is likely to be that the collective upregulation of cell cycle-promoting genes and downregulation of cell cyclesuppressing genes such as Rb, p53, p21 and p27 contribute to the increased proliferation of PAX5 − MCL cells. PAX5 − MCL cells also used the hyperactivity of existing prosurvival pathways, including the AKT/mTOR and MAPK/ERK pathways, to promote their growth (Figure 4a ). It is likely to be that IL-6 acts upstream of these pathways, because PAX5 − SP53 cells produced more IL-6 than control cells (Figure 4b) . The possible roles of platelet-derived growth factor receptor and epithelial growth factor receptor on PAX5 − MCL signaling should be further explored. Platelet-derived growth factor receptor has been implicated in increased AKT and STAT3 signaling, 47 and both platelet-derived growth factor receptor and epithelial growth factor receptor have been reported to synergize with IL-6 signaling, possibly leading to increased IL-6 signal sensitivity. [48] [49] [50] IL-6-related downstream genes were even upregulated in Jeko cells, which do not produce IL-6, suggesting that PAX5 can influence IL-6-related gene expression. In multiple myeloma KAS 6/1 cells, IL-6 treatment leads to TP53 promoter methylation, resulting in decreased TP53 expression levels. 51 Therefore, increased autocrine IL-6 expression in PAX5 − MCL cells may contribute to the reduction in TP53 gene expression via promoter hypermethylation.
Stromal cells probably represent the primary source of paracrine IL-6 in the bone marrow, as co-culturing PAX5 − MCL cells with HS-5 cells led to the upregulation of pSTAT3 signaling (Figure 4d ). Advanced MCL patients often show the involvement of extranodal sites, such as the bone marrow, and for malignant cells to survive in tissues other than their tissue of origin, adaptation to the local microenvironment is necessary. Increased autocrine IL-6 levels on Figure 7 . The roles PAX5 signaling in MCL dissemination and prognosis. A model depicting the observations made in this study. MCL patient blood and bone marrow, as well as blastoid MCL samples, displayed significantly lower transcript levels of PAX5. PAX5 − Jeko and SP53 MCL cells were generated to emulate this observed PAX5 expression gradient. PAX5 − cells exhibited increased proliferation, tumorigenesis, drug resistance, motility and adhesion to the bone marrow microenvironment in vitro and in vivo. PAX5 − MCL cells also exhibited elevated phosphorylation of AKT, mTOR, ERK and p38 MAPK.
PAX5 silencing could provide survival advantages to MCL cells in an environment that lacks a source of paracrine IL-6. Therefore, PAX5 downregulation could serve as an adaptive process that promotes survival in the local microenvironment. Pax5 − / − pro-B cells display increased lineage plasticity and differentiation into functional macrophages, granulocytes, dendritic cells, osteoclasts and natural killer cells in vivo. 7, 8 Adoptive transfer of Pax5 − / − B cells to immunodeficient mice led to the development of T cells, indicating that Pax5 downregulation induces mature B cells to acquire a plasticity that is similar to that of early progenitor cells. We did not directly examine the lineage differentiation of PAX5 − MCL cells due to other oncogenic mutations; however, the MCL cells exhibited significantly increased colony-forming ability in phytohemagglutinin leukocyte conditioned medium on PAX5 silencing. In addition, transferring PKH26 + PAX5 − MCL cells to xenografted mice increased the number of quiescent PKH26 + cells in these mice, indicating that PAX5 silencing in MCL affects the retention of quiescent cells. PKH26 labeling has been used to isolate long-term hematopoietic stem cells and cancer stem cells in some cancer types. 52 Our data support the concept that PAX5 downregulation promotes MCL cells to exhibit a more stem-like phenotype. However, the detailed molecular mechanisms underlying this process remain to be evaluated by RNA sequencing or chromatin immunoprecipitation sequencing.
Our high-throughput screening results further clarify the drugresistant nature of PAX5 − MCL cells. In particular, PAX5 − MCL cells were highly resistant to compounds that target PI3K/AKT/mTOR-, MEK/ERK-, platelet-derived growth factor receptor-and epithelial growth factor receptor-related pathways (Figure 6e ). Interestingly, fewer drugs killed TP53-null Jeko cells compared with wild-type SP53 cells, suggesting that the TP53 mutational status could have an impact on drug resistance in MCL. The compounds that we identified may serve as good candidates for novel MCL patient therapies; we plan to perform additional pre-clinical studies to narrow down this list of compounds for further studies.
Our discovery of a correlation of PAX5 levels with aggressive blastoid MCL is the first evidence of the clinical importance of reduced PAX5 levels to lymphoma progression (Figure 7 ). Our data also suggest that the PAX5 levels could be used as a prognostic marker for MCL patients. Collectively, our findings provide novel insight into the functions of PAX5 in human B-cell cancer and support a paradigm shift in understanding the pathogenesis of MCL.
